Significant Health Benefits Seen With Meeting ATS Air Quality Standard
THURSDAY, Jan. 20, 2022 (HealthDay News) — Meeting the American Thoracic Society (ATS)-recommended air quality standards (limit long-term fine particular matter to 8 µg/m3) would yield significant health benefits, according to a study published recen…
Learn MoreBreast Cancer Survivors Face Higher Risk for Hypertension, Diabetes
THURSDAY, Jan. 20, 2022 (HealthDay News) — Women with, versus without, a history of breast cancer have a higher incidence of hypertension and diabetes up to 10 years following diagnosis, according to a study published online Jan. 13 in the Journal of Clinical Oncology.
Marilyn L. Kwan, Ph.D., from Kaiser Permanente Northern California in Oakland, and colleagues matched (in a 1:5 ratio) 14,942 women with invasive breast cancer (diagnosed from 2005 to 2013) to noncancer controls based on birth year, race, and ethnicity. Rates of hypertension, diabetes, and dyslipidemia were compared by breast cancer status.
The researchers found that breast cancer cases had higher cumulative incidence rates of hypertension (10.9 versus 8.9 percent) and diabetes (2.1 versus 1.7 percent) after two years compared with controls, with higher diabetes incidence persisting after 10 years (9.3 versus 8.8 percent). Breast cancer cases had a higher risk for diabetes (subdistribution hazard ratios [sHR], 1.16) versus controls. Diabetes risk continued to be higher among cases treated with chemotherapy (sHR, 1.23), left-sided radiation (sHR, 1.29), or endocrine therapy (sHR, 1.23). For cases receiving left-sided radiation (sHR, 1.11) or endocrine therapy (sHR, 1.10), hypertension risk was higher. Higher risk was seen for cases with normal weight (body mass index, 2) both overall and within treatment subgroups versus controls.
“Study findings highlight patients with breast cancer as a vulnerable population at higher risk of cardiometabolic risk factors and support targeted cardiovascular surveillance by specific patient and treatment characteristics to mitigate these risks,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Learn MoreSame-Day Discharge Increasing for Hip, Knee Arthroplasty
THURSDAY, Jan. 20, 2022 (HealthDay News) — Same-day discharge (SDD) is becoming more common for both total hip arthroplasty (THA) and total knee arthroplasty (TKA), according to a study recently published online in the Journal of Arthroplasty.
Eytan M. Debbi, M.D., Ph.D., from the Hospital for Special Surgery in New York City, and colleagues used the PearlDiver All-Payer database to assess trends in primary, elective THA/TKA cases between 2010 and 2017.
The researchers found that of the 1,789,601 patients identified (68.8 percent TKA and 31.2 percent THA), 2.9 percent of TKAs and 2.2 percent of THAs were SDD. There was an increase in annual SDD rates, with a 15.8 percent mean annual change for SDD-THA and 11.1 percent for SDD-TKA. SDD patients were significantly younger and had fewer comorbidities. Overall, there was a slightly higher risk for complications requiring readmission for SDD-TKA versus non-SDD-TKA (odds ratio, 1.14; 95 percent confidence interval, 1.07 to 1.21; P
“SDD is becoming more common and likely safe with appropriate patient selection and postoperative monitoring,” the authors write.
One author disclosed financial ties to the biomedical industry.
Abstract/Full Text (subscription or payment may be required)
Learn MoreNearly Half of U.S. Adults Gained Weight During First Year of Pandemic
THURSDAY, Jan. 20, 2022 (HealthDay News) — Almost half of U.S. adults report gaining weight during the first year of the COVID-19 pandemic, according to a study published online in the January issue of Diabetes & Metabolic Syndrome: Clinical Research…
Learn MoreU.S. Insurers Could Spend Millions for Ivermectin Rx for COVID-19
THURSDAY, Jan. 20, 2022 (HealthDay News) — Insurers could prevent substantial waste by restricting prescription coverage for inappropriate use of ivermectin for COVID-19, according to a research letter published online Jan. 13 in the Journal of the A…
Learn MoreLong-Term Outcomes Described for Survivors of Childhood ALL
TURSDAY, Jan. 20, 2022 (HealthDay News) — In an article published online Dec. 29 in Cancers, long-term adverse and positive outcomes are described for survivors of childhood acute lymphoblastic leukemia (ALL).Charlotte Sleurs, Ph.D., from the Univers…
Learn MoreNomogram May Help Predict Survival in Primary Intestinal NHL
THURSDAY, Jan. 20, 2022 (HealthDay News) — A nomogram can assist clinicians in predicting cancer-specific survival in patients with primary intestinal non-Hodgkin lymphoma (PINHL), according to a study published online Dec. 20 in Cancer Management an…
Learn MoreEmergency Department Interventions Cut Opioid Rx Rates
THURSDAY, Jan. 20, 2022 (HealthDay News) — Most emergency department interventions aimed at cutting opioid prescribing cut the prescription rate but not the prescribed opioid quantity, according to a review published online Jan. 13 in JAMA Network Op…
Learn MoreFourth Vaccine Dose May Up COVID-19 Immunity in Kidney Transplant Recipients
THURSDAY, Jan. 20, 2022 (HealthDay News) — A fourth dose of an mRNA-based anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine may increase antispike immunoglobulin (Ig)G titers in kidney transplant recipients, according to a research letter published online Jan. 11 in the Annals of Internal Medicine.
Sophie Caillard, M.D., Ph.D., from the University Hospitals of Strasbourg in France, and colleagues examined whether a fourth dose of an mRNA-based anti-SARS-CoV-2 vaccine would increase antispike IgG titers in 92 kidney transplant recipients (34 received BNT162b2; 58 received mRNA-1273) with antispike IgG titers
The researchers found that no safety concerns were observed with the fourth dose. Median antispike IgG levels increased from 16.4 to 145 BAU/mL after a median of 29 days; 50 percent of patients reached the threshold of 143 BAU/mL. Patients who reached this threshold had a longer interval between transplant and fourth vaccine dose and less often received steroids. The percentage of patients with antispike IgG titers above 143 BAU/mL after the fourth dose was 48 and 52 percent for BNT162b2 and mRNA-1273, respectively; patients receiving mRNA-1273 had higher IgG titers (median 150 versus 122 BAU/mL). Only one patient was subsequently diagnosed with mild COVID-19; one month after the fourth dose, the patient’s antispike IgG level was 28 BAU/mL.
“We recognize that an increase in antispike IgG titers does not invariably provide protection from infection and disease, which is why we encourage longitudinal studies with a sufficient duration of follow-up to evaluate the risk for COVID-19 in patients like these after additional vaccine doses,” the authors write.
Two authors disclosed financial ties to the biopharmaceutical industry.
Learn MoreCOVID-19 Proning Teams Benefit From Wound Care Specialist Nurse
THURSDAY, Jan. 20, 2022 (HealthDay News) — The inclusion of a certified wound and skin care nurse on a multiprofessional prone-positioning team significantly reduces the odds of pressure injuries developing in patients hospitalized with severe COVID-…
Learn More